Literature DB >> 22157297

Implementing personalized medicine in a cancer center.

David A Fenstermacher1, Robert M Wenham, Dana E Rollison, William S Dalton.   

Abstract

In 2006, the Moffitt Cancer Center partnered with patients, community clinicians, industry, academia, and 17 hospitals in the United States to begin a personalized cancer care initiative called Total Cancer Care. Total Cancer Care was designed to collect tumor specimens and clinical data throughout a patient's lifetime, with the goal of finding "the right treatment, for the right patient, at the right time." Because Total Cancer Care is a partnership with the patient and involves collection of clinical data and tumor specimens for research purposes, a formal protocol and patient consent process was developed, and an information technology platform was constructed to provide a robust "warehouse" for clinical and molecular profiling data. To date, more than 76,000 cancer patients from Moffitt and consortium medical centers have been enrolled in the protocol. The Total Cancer Care initiative has developed many of the capabilities and resources that are building the foundation of personalized medicine.

Entities:  

Mesh:

Year:  2011        PMID: 22157297      PMCID: PMC3240816          DOI: 10.1097/PPO.0b013e318238216e

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  14 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  caCORE: a common infrastructure for cancer informatics.

Authors:  Peter A Covitz; Frank Hartel; Carl Schaefer; Sherri De Coronado; Gilberto Fragoso; Himanso Sahni; Scott Gustafson; Kenneth H Buetow
Journal:  Bioinformatics       Date:  2003-12-12       Impact factor: 6.937

3.  ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling.

Authors:  Smitha Pillai; Wasia Rizwani; Xueli Li; Bhupendra Rawal; Sajitha Nair; Michael J Schell; Gerold Bepler; Eric Haura; Domenico Coppola; Srikumar Chellappan
Journal:  Mol Cell Biol       Date:  2011-05-23       Impact factor: 4.272

Review 4.  The 2010 Health Care Reform Act: a potential opportunity to advance cancer research by taking cancer personally.

Authors:  William S Dalton; Daniel M Sullivan; Timothy J Yeatman; David A Fenstermacher
Journal:  Clin Cancer Res       Date:  2010-12-15       Impact factor: 12.531

5.  ARRB1-mediated regulation of E2F target genes in nicotine-induced growth of lung tumors.

Authors:  Piyali Dasgupta; Wasia Rizwani; Smitha Pillai; Rebecca Davis; Sarmistha Banerjee; Kevin Hug; Mark Lloyd; Domenico Coppola; Eric Haura; Srikumar P Chellappan
Journal:  J Natl Cancer Inst       Date:  2011-01-06       Impact factor: 13.506

Review 6.  Proteomic contributions to personalized cancer care.

Authors:  John M Koomen; Eric B Haura; Gerold Bepler; Rebecca Sutphen; Elizabeth R Remily-Wood; Kaaron Benson; Mohamad Hussein; Lori A Hazlehurst; Timothy J Yeatman; Lynne T Hildreth; Thomas A Sellers; Paul B Jacobsen; David A Fenstermacher; William S Dalton
Journal:  Mol Cell Proteomics       Date:  2008-07-29       Impact factor: 5.911

7.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

8.  On the eve of personalized medicine in oncology.

Authors:  Timothy J Yeatman; James Mule; William S Dalton; Dan Sullivan
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

9.  Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform.

Authors:  Steven Eschrich; Hongling Zhang; Haiyan Zhao; David Boulware; Ji-Hyun Lee; Gregory Bloom; Javier F Torres-Roca
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-01       Impact factor: 7.038

10.  Review of erlotinib in the treatment of advanced non-small cell lung cancer.

Authors:  Kristen N Ganjoo; Heather Wakelee
Journal:  Biologics       Date:  2007-12
View more
  72 in total

1.  Association Between Computed Tomographic Features and Kirsten Rat Sarcoma Viral Oncogene Mutations in Patients With Stage I Lung Adenocarcinoma and Their Prognostic Value.

Authors:  Hua Wang; Matthew B Schabath; Ying Liu; Olya Stringfield; Yoganand Balagurunathan; John J Heine; Steven A Eschrich; Zhaoxiang Ye; Robert J Gillies
Journal:  Clin Lung Cancer       Date:  2015-11-12       Impact factor: 4.785

2.  Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Authors:  Jennifer Permuth-Wey; Dung-Tsa Chen; William J Fulp; Sean J Yoder; Yonghong Zhang; Christina Georgeades; Kazim Husain; Barbara Ann Centeno; Anthony M Magliocco; Domenico Coppola; Mokenge Malafa
Journal:  Cancer Prev Res (Phila)       Date:  2015-09

3.  Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma.

Authors:  Tobin Strom; Javier F Torres-Roca; Akash Parekh; Arash O Naghavi; Jimmy J Caudell; Daniel E Oliver; Jane L Messina; Nikhil I Khushalani; Jonathan S Zager; Amod Sarnaik; James J Mulé; Andy M Trotti; Steven A Eschrich; Vernon K Sondak; Louis B Harrison
Journal:  J Natl Compr Canc Netw       Date:  2017-04       Impact factor: 11.908

4.  Transcriptomic Differences between Primary Colorectal Adenocarcinomas and Distant Metastases Reveal Metastatic Colorectal Cancer Subtypes.

Authors:  Yasmin Kamal; Stephanie L Schmit; Hannah J Hoehn; Christopher I Amos; H Robert Frost
Journal:  Cancer Res       Date:  2019-06-25       Impact factor: 12.701

5.  Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.

Authors:  Nancy K Gillis; Markus Ball; Qing Zhang; Zhenjun Ma; YuLong Zhao; Sean J Yoder; Maria E Balasis; Tania E Mesa; David A Sallman; Jeffrey E Lancet; Rami S Komrokji; Alan F List; Howard L McLeod; Melissa Alsina; Rachid Baz; Kenneth H Shain; Dana E Rollison; Eric Padron
Journal:  Lancet Oncol       Date:  2016-12-04       Impact factor: 41.316

Review 6.  Drug development and clinical trials--the path to an approved cancer drug.

Authors:  Eric H Rubin; D Gary Gilliland
Journal:  Nat Rev Clin Oncol       Date:  2012-02-28       Impact factor: 66.675

7.  Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers.

Authors:  Nishi Kothari; Jamie K Teer; Andrea M Abbott; Thejal Srikumar; Yonghong Zhang; Sean J Yoder; Andrew S Brohl; Richard D Kim; Damon R Reed; David Shibata
Journal:  Cancer       Date:  2016-05-31       Impact factor: 6.860

8.  Empowering underserved populations through cancer prevention and early detection.

Authors:  Venessa Rivera-Colón; Roberto Ramos; Jenna L Davis; Myriam Escobar; Nikki Ross Inda; Linda Paige; Jeannette Palencia; Maria Vives; Cathy G Grant; B Lee Green
Journal:  J Community Health       Date:  2013-12

9.  Tumour radiosensitivity is associated with immune activation in solid tumours.

Authors:  Tobin Strom; Louis B Harrison; Anna R Giuliano; Michael J Schell; Steven A Eschrich; Anders Berglund; William Fulp; Ram Thapa; Domenico Coppola; Sungjune Kim; Jessica Frakes; John Foekens; James J Mulé; Javier F Torres-Roca
Journal:  Eur J Cancer       Date:  2017-08-29       Impact factor: 9.162

10.  Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma.

Authors:  Gabriella M Anic; Vernon K Sondak; Jane L Messina; Neil A Fenske; Jonathan S Zager; Basil S Cherpelis; Ji-Hyun Lee; William J Fulp; Pearlie K Epling-Burnette; Jong Y Park; Dana E Rollison
Journal:  Cancer Epidemiol       Date:  2013-03-21       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.